BioSpace News Archive

BioCapital

Processa Pharmaceuticals Raises $6.88 Million From Private Placements

Processa Pharmaceuticals, Inc. (OTC: PCSA) is pleased to announce it has raised a total of $6.88 million from private placements.

June 1, 2018
·
4 min read
Pharm Country

Integral Molecular Celebrates Epitope Mapping Milestone of 1,000 Epitopes

Integral Molecular celebrates a milestone of mapping 1,000 epitopes for customers, collaborators, and the NIH.

June 1, 2018
·
2 min read
FDA

FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved the 2-mg dose of OLUMIANT® (baricitinib), a once-daily oral medication for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA).

June 1, 2018
·
16 min read
BioCapital

CHADIS Named App of the Month for June 2018 by Allscripts

CHADIS, from Total Child Health was named app of the month by Allscripts for June 2018.

June 1, 2018
·
2 min read
BioForest

Avant Diagnostics to Present at LD Micro

Avant Diagnostics, Inc. announced that its new President & CEO, Mick Ruxin, M.D., will be presenting a corporate overview at the 8th Annual LD Micro Invitational.

June 1, 2018
·
3 min read
Genetown

PerkinElmer to Present at Goldman Sachs Global Healthcare Conference

PerkinElmer, Inc. announced that the Company will present at the 38th annual Goldman Sachs Global Healthcare Conference.

June 1, 2018
·
1 min read
Drug Development

IMBRUVICA® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström’s Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin’s Lymphoma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from a pre-planned interim analysis of the Phase 3 iNNOVATE (PCYC-1127) study evaluating the investigational use of IMBRUVICA® (ibrutinib) in combination with rituximab in relapsed/refractory and treatment-naïve patients with Waldenström’s macroglobulinemia (WM).

June 1, 2018
·
15 min read
Drug Development

Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma

Amgen announced results from the Phase 3 A.R.R.O.W. trial of a once-weekly KYPROLIS®

June 1, 2018
·
19 min read
Drug Development

Clinical Data for Zymeworks’ Novel Bispecific Antibody, ZW25, Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Zymeworks Inc. announced the presentation of ZW25 clinical data by Funda Meric-Bernstam, MD, Principal Investigator for the ZW25 study at the University of Texas MD Anderson Cancer Center.

June 1, 2018
·
9 min read
Business

Empower Clinics Announces Medical Cannabis Product Distribution Agreement in Oregon

Empower Clinics Inc. announced that it has signed a distribution agreement with Nova Paths

June 1, 2018
·
3 min read